WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000029390) CRYSTALLINE (-)-6- CHLORO-4- CYCLOPROPYLETHYNYL- 4-TRIFLUOROMETHYL- 3,4-DIHYDRO- 2(1H)-QUINAZOLINONE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/029390    International Application No.:    PCT/US1999/027354
Publication Date: 25.05.2000 International Filing Date: 18.11.1999
Chapter 2 Demand Filed:    29.05.2000    
IPC:
C07D 239/78 (2006.01), C07D 239/80 (2006.01)
Applicants: DU PONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza 974 Centre Road Wilmington, DE 19807 (US)
Inventors: RABEL, Shelly, R.; (US).
PATEL, Mona; (US).
PARSONS, Rodney, Lawrence, Jr.; (US)
Agent: VANATTEN, Mary, K.; Du Pont Pharmaceuticals Company Legal Patent Records Center 1007 Market Street Wilmington, DE 19898 (US)
Priority Data:
60/109,244 19.11.1998 US
Title (EN) CRYSTALLINE (-)-6- CHLORO-4- CYCLOPROPYLETHYNYL- 4-TRIFLUOROMETHYL- 3,4-DIHYDRO- 2(1H)-QUINAZOLINONE
(FR) (-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-3,4-DIHYDRO-2(1H)-QUINAZOLINONE CRISTALLINE
Abstract: front page image
(EN)The potent reverse transcriptase inhibitor (-)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone is produced in solvate and crystalline form. These forms are designated Forms 1 and 2, and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV).
(FR)Selon cette invention, on produit un puissant inhibiteur de la reverse-transcriptase, (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone, sous une forme soluble ou cristalline. Ces formes, désignées 'forme 1' et 'forme 2', sont caractérisées par la diffraction des rayons X dans la poudre et par une calorimétrie à balayage différentielle. Les compositions pharmaceutiques et les procédés de l'invention peuvent servir dans le traitement du virus de l'immunodéficience humaine, ou VIH.
Designated States: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA.
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)